2485 - Diabetes (Answered)

Luciana Berger
To ask the Secretary of State for Health, what the evidential basis was for NICE's draft clinical guidelines for the management of type 1 and type 2 diabetes in adults.

George Freeman

The evidence considered by the National Institute for Health and Care Excellence (NICE) in the development of its guidance is available on the NICE website.

The evidence for NICE’s draft clinical guideline on type 1 diabetes is available at:

2391 - NHS England: BioMarin (Answered)

Greg Mulholland
To ask the Secretary of State for Health, what meetings NHS England has had with the pharmaceutical company BioMarin over the last 12 months; when those meetings took place; and if he will publish the minutes of each such meeting.

George Freeman

2415 - Medical Records: Data Protection (Answered)

Mr Roger Godsiff
To ask the Secretary of State for Health, whether it is his policy that opt-outs from care.data will apply to all patients and all flows of data from GP records for all purposes other than the delivery of direct care, regardless of which NHS body or other organisation such data is intended to go to.

George Freeman

1793 - Leukaemia: Medical Treatments (Answered)

Jim Shannon
To ask the Secretary of State for Health, if he will discuss with the British Medical Association and other medical bodies the treatment of leukemia with T-cells.

George Freeman

1566 - Nabiximols (Answered)

Steve McCabe
To ask the Secretary of State for Health, whether NICE plans to allow routine access on the NHS in England to the Sativex form of nabiximols.

George Freeman

The National Institute for Health and Care Excellence (NICE) published a clinical guideline on multiple sclerosis in 2014 that does not recommend Sativex (nabiximols) as a clinically and cost effective use of National Health Service resources. This is available at:

1563 - Nabiximols (Answered)

Steve McCabe
To ask the Secretary of State for Health, whether NICE plans to conduct a full technology appraisal of Sativex form of nabiximols to allow the drug to be prescribed on the NHS.

George Freeman

The National Institute for Health and Care Excellence (NICE) published a clinical guideline on multiple sclerosis in 2014 that does not recommend Sativex (nabiximols) as a clinically and cost effective use of National Health Service resources. This is available at:

1681 - Erythromycin: Pregnant Women (Answered)

Jim Shannon
To ask the Secretary of State for Health, if he will discuss with the British Medical Association and other medical bodies the potential effects of erythromycin on unborn babies and pregnant women.

George Freeman

The Department has no plans to discuss the potential effects of erythromycin on unborn babies or pregnant women with the British Medical Association and other medical bodies.

1738 - Heart Diseases: Stem Cells (Answered)

Jim Shannon
To ask the Secretary of State for Health, what estimate he has made of the likely timescale for making available on the NHS treatment for heart disease using stem cells.

George Freeman

The Department is aware of the research on the use of adult stem cells to treat heart disease and supports the development of regenerative medicine technologies. As this therapy is still in the clinical trial stage, it is not possible to make any meaningful estimate of when such treatments will be available on the National Health Service.

1564 - Nabiximols (Answered)

Steve McCabe
To ask the Secretary of State for Health, whether he plans to allow routine access on the NHS in England to the medicine Sativex.

George Freeman

The National Institute for Health and Care Excellence (NICE) published a clinical guideline on multiple sclerosis in 2014 that does not recommend Sativex (nabiximols) as a clinically and cost effective use of National Health Service resources. This is available at:

1565 - Nabiximols (Answered)

Steve McCabe
To ask the Secretary of State for Health, if he will direct NICE to conduct a full technology appraisal of the Sativex form of nabiximols to allow the drug to be prescribed on the NHS.

George Freeman

The National Institute for Health and Care Excellence (NICE) published a clinical guideline on multiple sclerosis in 2014 that does not recommend Sativex (nabiximols) as a clinically and cost effective use of National Health Service resources. This is available at:

Pages